Kymera Therapeutics (KYMR) Stock Forecast, Price Target & Predictions
KYMR Stock Forecast
Kymera Therapeutics stock forecast is as follows: an average price target of $51.10 (represents a 10.89% upside from KYMR’s last price of $46.08) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
KYMR Price Target
The average price target for Kymera Therapeutics (KYMR) is $51.10 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $80.00 to $31.00. This represents a potential 10.89% upside from KYMR's last price of $46.08.
KYMR Analyst Ratings
According to 10 Wall Street analysts, Kymera Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for KYMR stock is 0 'Strong Buy' (0.00%), 6 'Buy' (60.00%), 4 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Kymera Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 26, 2024 | Andy Chen | Wolfe Research | $65.00 | $47.78 | 36.04% | 41.06% |
| Aug 08, 2024 | Andrew Fein | H.C. Wainwright | $60.00 | $40.31 | 48.85% | 30.21% |
| Jun 17, 2024 | Andrew Fein | H.C. Wainwright | $46.00 | $32.29 | 42.46% | -0.17% |
| May 23, 2024 | Edward Tenthoff | Piper Sandler | $56.00 | $34.84 | 60.76% | 21.53% |
| May 03, 2024 | Jeff Jones | Oppenheimer | $52.00 | $36.30 | 43.25% | 12.85% |
| Jan 03, 2023 | - | Wells Fargo | $42.00 | $24.71 | 69.97% | -8.85% |
| Dec 19, 2022 | - | Morgan Stanley | $41.00 | $27.05 | 51.56% | -11.02% |
| Dec 16, 2022 | - | Goldman Sachs | $52.00 | $28.26 | 84.01% | 12.85% |
| Dec 15, 2022 | - | Leerink Partners | $31.00 | $29.62 | 4.66% | -32.73% |
| Dec 06, 2022 | Michael Turits | Morgan Stanley | $45.20 | $29.11 | 55.27% | -1.91% |
The latest Kymera Therapeutics stock forecast, released on Aug 26, 2024 by Andy Chen from Wolfe Research, set a price target of $65.00, which represents a 36.04% increase from the stock price at the time of the forecast ($47.78), and a 41.06% increase from KYMR last price ($46.08).
Kymera Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 5 |
| Avg Price Target | $65.00 | $57.00 | $55.80 |
| Last Closing Price | $46.08 | $46.08 | $46.08 |
| Upside/Downside | 41.06% | 23.70% | 21.09% |
In the current month, the average price target of Kymera Therapeutics stock is $65.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 41.06% increase as opposed to Kymera Therapeutics's last price of $46.08. This month's average price target is up 14.04% compared to last quarter, and up 16.49% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 09, 2024 | Wolfe Research | Buy | Buy | Hold |
| Aug 26, 2024 | Wolfe Research | - | Outperform | Upgrade |
| Aug 14, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 12, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Aug 12, 2024 | Wells Fargo | Buy | Buy | Hold |
| Aug 12, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Aug 08, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 17, 2024 | Oppenheimer | Buy | Buy | Hold |
| Jun 17, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
Kymera Therapeutics's last stock rating was published by Wolfe Research on Sep 09, 2024. The company gave KYMR a "Buy" rating, the same as its previous rate.
Kymera Therapeutics Financial Forecast
Kymera Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $4.73M | $16.51M | $9.47M | $16.14M | $9.55M | - | $9.62M | $15.28M | $20.34M | $18.52M | $18.70M | $12.79M | $14.53M |
| Avg Forecast | $8.30M | $18.18M | $10.70M | $11.62M | $13.56M | $10.34M | $12.55M | $14.24M | $41.94M | $15.97M | $14.06M | $14.15M | $22.05M | $15.51M | $14.24M | $18.75M | $21.31M | $19.61M | $18.81M | $19.05M | $21.60M | $84.00M |
| High Forecast | $15.42M | $33.77M | $19.88M | $21.58M | $25.19M | $17.29M | $23.31M | $26.44M | $95.22M | $32.68M | $26.11M | $26.29M | $40.96M | $28.81M | $14.24M | $42.38M | $48.18M | $44.33M | $42.53M | $43.07M | $48.83M | $189.88M |
| Low Forecast | $2.40M | $5.27M | $3.10M | $3.37M | $3.93M | $3.56M | $3.64M | $4.12M | $10.31M | $8.00M | $4.07M | $4.10M | $6.39M | $4.49M | $14.24M | $315.06K | $358.20K | $329.60K | $316.20K | $320.20K | $363.02K | $1.41M |
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 9 | 10 | 15 | 9 | 9 | 13 | 13 | 6 | 5 | 6 | 6 | 6 | 6 | 10 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.30% | 1.17% | 0.67% | 0.73% | 0.62% | - | 0.51% | 0.72% | 1.04% | 0.98% | 0.98% | 0.59% | 0.17% |
Kymera Therapeutics's average Quarter revenue forecast for Dec 23 based on 10 analysts is $41.94M, with a low forecast of $10.31M, and a high forecast of $95.22M. KYMR's average Quarter revenue forecast represents a 787.07% increase compared to the company's last Quarter revenue of $4.73M (Sep 23).
Kymera Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 9 | 10 | 15 | 9 | 9 | 13 | 13 | 6 | 5 | 6 | 6 | 6 | 6 | 10 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-57.51M | $-43.38M | $-40.87M | $-34.81M | $-42.20M | - | $-35.96M | $-33.16M | $-27.84M | $-24.08M | $-12.57M | $-12.16M | $-7.47M |
| Avg Forecast | $-8.30M | $-18.18M | $-10.70M | $-11.62M | $-13.56M | $-10.34M | $-12.55M | $-53.18M | $-41.94M | $-15.97M | $-14.06M | $-42.04M | $-22.05M | $-26.19M | $-14.24M | $-33.23M | $-27.92M | $-23.81M | $-14.91M | $-10.09M | $-21.60M | $-5.55M |
| High Forecast | $-2.40M | $-5.27M | $-3.10M | $-3.37M | $-3.93M | $-3.56M | $-3.64M | $-42.54M | $-10.31M | $-8.00M | $-4.07M | $-33.63M | $-6.39M | $-20.95M | $-14.24M | $-26.59M | $-22.34M | $-19.05M | $-11.93M | $-8.07M | $-363.02K | $-4.44M |
| Low Forecast | $-15.42M | $-33.77M | $-19.88M | $-21.58M | $-25.19M | $-17.29M | $-23.31M | $-63.81M | $-95.22M | $-32.68M | $-26.11M | $-50.45M | $-40.96M | $-31.43M | $-14.24M | $-39.88M | $-33.51M | $-28.57M | $-17.89M | $-12.11M | $-48.83M | $-6.66M |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.60% | 3.09% | 0.97% | 1.58% | 1.61% | - | 1.08% | 1.19% | 1.17% | 1.62% | 1.25% | 0.56% | 1.35% |
undefined analysts predict KYMR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kymera Therapeutics's previous annual EBITDA (undefined) of $NaN.
Kymera Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 9 | 10 | 15 | 9 | 9 | 13 | 13 | 6 | 5 | 6 | 6 | 6 | 6 | 10 | 10 |
| Net Income | - | - | - | - | - | - | - | - | - | $-52.87M | $-38.80M | $-36.59M | $-34.05M | $-41.12M | - | $-36.44M | $-33.95M | $-28.58M | $-24.66M | $-13.07M | $-12.69M | $-7.99M |
| Avg Forecast | $-74.13M | $-65.99M | $-67.69M | $-66.16M | $-62.21M | $-61.11M | $-49.78M | $-54.26M | $-29.48M | $-46.52M | $-46.44M | $-42.89M | $-46.06M | $-26.89M | $-48.61M | $-33.90M | $-28.55M | $-24.44M | $-15.27M | $-10.50M | $-3.02M | $-5.93M |
| High Forecast | $-5.67M | $-5.04M | $-5.17M | $-5.06M | $-4.76M | $-49.33M | $-3.81M | $-43.40M | $30.15M | $-30.37M | $-3.55M | $-34.31M | $-3.52M | $-21.51M | $-48.61M | $-27.12M | $-22.84M | $-19.56M | $-12.21M | $-8.40M | $841.03K | $-4.75M |
| Low Forecast | $-156.73M | $-139.53M | $-143.12M | $-139.89M | $-131.52M | $-75.10M | $-105.24M | $-65.11M | $-57.62M | $-58.16M | $-98.18M | $-51.47M | $-97.38M | $-32.27M | $-48.61M | $-40.69M | $-34.26M | $-29.33M | $-18.32M | $-12.60M | $-7.98M | $-7.12M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.14% | 0.84% | 0.85% | 0.74% | 1.53% | - | 1.07% | 1.19% | 1.17% | 1.62% | 1.25% | 4.20% | 1.35% |
Kymera Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KYMR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Kymera Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 9 | 10 | 15 | 9 | 9 | 13 | 13 | 6 | 5 | 6 | 6 | 6 | 6 | 10 | 10 |
| SG&A | - | - | - | - | - | - | - | - | - | $14.12M | $14.13M | $12.56M | $11.64M | $10.56M | - | $10.61M | $11.74M | $10.67M | $8.03M | $5.91M | $5.17M | $6.84M |
| Avg Forecast | $8.95M | $19.61M | $11.54M | $12.53M | $14.62M | $11.15M | $13.54M | $15.35M | $45.22M | $17.22M | $15.16M | $12.41M | $23.78M | $10.03M | $15.35M | $9.81M | $9.89M | $9.12M | $4.97M | $4.74M | $23.29M | $5.08M |
| High Forecast | $16.63M | $36.41M | $21.43M | $23.27M | $27.16M | $18.64M | $25.14M | $28.51M | $102.68M | $35.24M | $28.15M | $14.89M | $44.16M | $12.04M | $15.35M | $11.77M | $11.86M | $10.95M | $5.96M | $5.69M | $52.65M | $6.10M |
| Low Forecast | $2.59M | $5.68M | $3.34M | $3.63M | $4.23M | $3.84M | $3.92M | $4.45M | $11.12M | $8.63M | $4.39M | $9.92M | $6.89M | $8.03M | $15.35M | $7.85M | $7.91M | $7.30M | $3.98M | $3.80M | $391.44K | $4.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.82% | 0.93% | 1.01% | 0.49% | 1.05% | - | 1.08% | 1.19% | 1.17% | 1.62% | 1.25% | 0.22% | 1.35% |
Kymera Therapeutics's average Quarter SG&A projection for Dec 23 is $45.22M, based on 10 Wall Street analysts, with a range of $11.12M to $102.68M. The forecast indicates a 220.28% rise compared to KYMR last annual SG&A of $14.12M (Sep 23).
Kymera Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 9 | 10 | 15 | 9 | 9 | 13 | 13 | 6 | 5 | 6 | 6 | 6 | 6 | 10 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.90 | $-0.67 | $-0.63 | $-0.59 | $-0.75 | - | $-0.71 | $-0.66 | $-0.56 | $-0.55 | $-0.29 | $-0.29 | $-0.39 |
| Avg Forecast | $-1.01 | $-0.90 | $-0.93 | $-0.91 | $-0.85 | $-0.84 | $-0.68 | $-0.72 | $-0.40 | $-0.64 | $-0.64 | $-0.68 | $-0.63 | $-0.76 | $-0.69 | $-0.67 | $-0.47 | $-0.37 | $-0.26 | $-0.15 | $-0.05 | $0.72 |
| High Forecast | $-0.08 | $-0.07 | $-0.07 | $-0.07 | $-0.07 | $-0.68 | $-0.05 | $-0.06 | $0.41 | $-0.42 | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.69 | $0.19 | $0.13 | $0.10 | $0.07 | $0.04 | $0.01 | $1.89 |
| Low Forecast | $-2.15 | $-1.91 | $-1.96 | $-1.91 | $-1.80 | $-1.03 | $-1.44 | $-1.52 | $-0.79 | $-0.80 | $-1.34 | $-1.45 | $-1.33 | $-1.61 | $-0.69 | $-1.76 | $-1.23 | $-0.97 | $-0.68 | $-0.39 | $-0.14 | $-0.20 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.41% | 1.05% | 0.92% | 0.94% | 0.99% | - | 1.06% | 1.41% | 1.52% | 2.12% | 1.96% | 5.61% | -0.54% |
According to undefined Wall Street analysts, Kymera Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KYMR previous annual EPS of $NaN (undefined).
Kymera Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| STTK | Shattuck Labs | $3.81 | $12.00 | 214.96% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| PRLD | Prelude Therapeutics | $2.77 | $6.25 | 125.63% | Sell |
| FHTX | Foghorn Therapeutics | $9.72 | $18.00 | 85.19% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| NRIX | Nurix Therapeutics | $24.80 | $27.57 | 11.17% | Buy |
| KYMR | Kymera Therapeutics | $46.08 | $51.10 | 10.89% | Buy |
| AGIO | Agios Pharmaceuticals | $46.69 | $47.50 | 1.73% | Buy |
KYMR Forecast FAQ
Is Kymera Therapeutics a good buy?
Yes, according to 10 Wall Street analysts, Kymera Therapeutics (KYMR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 60.00% of KYMR's total ratings.
What is KYMR's price target?
Kymera Therapeutics (KYMR) average price target is $51.1 with a range of $31 to $80, implying a 10.89% from its last price of $46.08. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Kymera Therapeutics stock go up soon?
According to Wall Street analysts' prediction for KYMR stock, the company can go up by 10.89% (from the last price of $46.08 to the average price target of $51.1), up by 73.61% based on the highest stock price target, and down by -32.73% based on the lowest stock price target.
Can Kymera Therapeutics stock reach $70?
KYMR's highest twelve months analyst stock price target of $80 supports the claim that Kymera Therapeutics can reach $70 in the near future.
What is Kymera Therapeutics's current price target trend?
1 Wall Street analyst forecast a $65 price target for Kymera Therapeutics (KYMR) this month, up 41.06% from its last price of $46.08. Compared to the last 3 and 12 months, the average price target increased by 23.70% and increased by 21.09%, respectively.
What are Kymera Therapeutics's analysts' financial forecasts?
Kymera Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $50.69M (high $92.23M, low $15.25M), average EBITDA is $-89.632M (high $-53.667M, low $-130M), average net income is $-227M (high $-101M, low $-377M), average SG&A $54.66M (high $99.45M, low $16.44M), and average EPS is $-3.09 (high $-0.847, low $-5.792). KYMR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $48.81M (high $90.65M, low $14.14M), average EBITDA is $-48.813M (high $-14.135M, low $-90.653M), average net income is $-274M (high $-20.945M, low $-579M), average SG&A $52.63M (high $97.75M, low $15.24M), and average EPS is $-3.75 (high $-0.287, low $-7.929).
Did the KYMR's actual financial results beat the analysts' financial forecasts?
Based on Kymera Therapeutics's last annual report (Dec 2022), the company's revenue was $46.83M, which missed the average analysts forecast of $70.55M by -33.63%. Apple's EBITDA was $-155M, beating the average prediction of $-95.714M by 61.56%. The company's net income was $-152M, missing the average estimation of $-155M by -2.34%. Apple's SG&A was $43.83M, missing the average forecast of $58.97M by -25.67%. Lastly, the company's EPS was $-2.82, beating the average prediction of $-2.745 by 2.72%. In terms of the last quarterly report (Sep 2023), Kymera Therapeutics's revenue was $4.73M, missing the average analysts' forecast of $15.97M by -70.40%. The company's EBITDA was $-57.509M, beating the average prediction of $-15.972M by 260.06%. Kymera Therapeutics's net income was $-52.867M, beating the average estimation of $-46.525M by 13.63%. The company's SG&A was $14.12M, missing the average forecast of $17.22M by -18.01%. Lastly, the company's EPS was $-0.9, beating the average prediction of $-0.637 by 41.33%